Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFT505 TQT Study in Healthy Volunteers
NCT02091310Phase 1Completed
- Sponsor
- Genfit
- Start
- Feb 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elafibranor in Nonalcoholic steatohepatitis (NASH) (7 arms), sponsored by Genfit. Primary endpoints: Safety parameters (AEs, VS, ECG, Labs) at 14 days and QTcF Interval at 14 days. Started Feb 2014; status: completed.
02
Drugs
elafibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02091310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091310.